# Fudan University: Phase 2 study in Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma (62 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Fudan University |
| Sponsor type | Academic and hospital |
| Study | Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ |
| NCT ID | NCT07912957 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma |
| Intervention types | drug |
| Target enrollment | 62 |
| Site countries | China |
| Posted | 2026-11-03 |
| Planned start | 2026-11-01 |
| Event | Newly registered study |
| Event date | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07912957). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.